Home Contact

Emidom (Domperidone)


EMIDOM (Domperidone) is a dopamine antagonist. Since it can't readily enter the central nervous system due to blood-brain barrier, its effects are confined to the periphery and acts principally at the receptor in the chemoreceptor trigger zone.


EMIDOM Tablet                    : Each film coated tablet contains Domperidone Maleate BP which is equivalent to 10 mg of Domperidone.

EMIDOM Suspension            : Each 5 ml suspension contains Domperidone BP 5 mg.

EMIDOM Paediatric Drops     : Each ml drop contains Domperidone BP 5 mg.


  1. Stimulation of gut mobility :

                a) Non-ulcer dyspepsia      b) Esophageal reflux, reflux esophagitis and gastritis c) Diabetic gastroparesis d) Functional dyspepsia

                e) Speeding barium transit in 'follow-through' radiological studies

  1. Prevention and symptomatic relief of acute nausea and vomiting from any cause including cytotoxic therapy, radio therapy and anti-parkinsonism therapy
  2. In the prophylactic treatment of migraine


EMIDOM tablet should be taken 15-30 minutes before meal In case of acute nausea and vomiting the recommended oral dose

Adults: 10-20 mg (1-2 EMIDOM Tablet or 10-20 ml EMIDOM Suspension) every 4-8 hours daily.

Children: 2- 4 ml EMIDOM Suspension/10 kg or 0.4- 0.8 ml EMIDOM Drops / 10 kg body weight every 4-8 hours daily. In case of functional  dyspepsia

Adults: 10-20 mg (1-2 EMIDOM Tablet or 10-20 ml EMIDOM Suspension) 3 times daily orally before meal and at night.

Children: Not recommended. For acute nausea, vomiting and functional dyspepsia, maximum period of treatment is 12 weeks.


Domperidone is contraindicated in patients having known hypersensitivity to this drug and in case of neonates.


Domperidone should be used with absolute caution in case of children because there may be an increased risk of extra-pyramidal reactions in young children because of an incompletely developed blood-brain barrier. Since Domperidone is highly metabolized in liver, it should be used with caution in patient with hepatic impairment.


Domperidone may produce hyperprolactinemia (1.3%). This may result in galactorrhea, gynaecomastia (breast enlargement), soreness and reduced libido. Dry mouth (1.9%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhoea (0.2%), skin rash and itching (0.1%) may occur during treatment with Domperidone. Extra-pyramidal reactions are seen in 0.25% of patients in clinical studies.


Pregnant women: The safety of Domperidone has not been proven and it is therefore not recommended during pregnancy. Animal studies have not demonstrated teratogenic effects on the fetus.

Lactating mother : Domperidone may precipitate galactorrhea and improve post-natal location. It is secreted in breast milk but in very small quantities insufficient to be considered harmful.


Domperidone may reduce the risk of hypoprolactinemic effect of bromocriptine and cabergoline. The action of Domperidone on GI function may be antagonized by antimuscarinics and opioid analgesics.


There are no reported cases of overdosage.


EMIDOM Tablet                :  Each box contains 10x10 tablets in blister pack.

EMIDOM Suspension        :  Each glass bottle contains 60 ml/100 ml suspension.

EMIDOM Paediatric Drops : Each glass bottle contains 15 ml Paediatric Drops.


News & Notice Board